An alternative therapeutic approach to blocking immunosuppressive checkpoint molecules has been to enhance T-cell activation and anti-tumor response via agonists to co-stimulatory surface receptors, such as 4-1BB, GITR, CD27, and OX40. Here, TNFRSF18 is linked to neoplasm.